Jeffrey Jensen

Mr. Jensen joined their team in March 2020 and is responsible for the success of their clinical programs through leadership, strategic oversight, and team direction. From 2016 through 2019, he served as Senior VP of Clinical Development at La Jolla Pharmaceutical Co, where he led the clinical and global safety teams, achieving FDA and EMA approval for an investigational synthetic human peptide (Giapreza®).

Mr. Jensen has over 30 years of experience in drug development at biotech and pharmaceutical companies in the U.S. and Europe. Previously, he was Vice President of Clinical Operations and Clinical Lead at Pfizer, leading the development operations team for axitinib (Inlyta®), and held senior positions at several biotechs and contract research companies (e.g., Metabasis, Excaliard, Syneos, PPD, Quintiles). He specializes in managing global teams and leading partnerships with research investigators and key opinion leaders. Mr. Jensen received his B.S. in Biochemistry and Biophysics from Oregon State University.